Stop Ovarian Cancer Young; Effect of the Opportunistic Salpingectomy on Age of Menopause
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Feb 16, 2021
Trial Information
Current as of August 29, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The aim of this study is to evaluate the long-term safety of on the onset of menopause. To investigate the effect of Opportunistic Salpingectomy on the age of menopause, we will compare age of menopause in women who underwent sterilization through opportunistic salpingectomy with a control group consisting of women who underwent sterilization by tubal ligation or who had no sterilization.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Intervention group
- • Undergoing an Opportunistic Salpingectomy as sterilization method
- • Premenopausal status at enrolment
- • Age between 30 and 45 years
- • Will have residual ovarian tissue after surgery
- • Able to understand the written or spoken Dutch language
- • Gives consent for participating in surveys
- • Control group
- • Premenopausal status at enrolment
- • Either sterilization by tubal ligation or no sterilization at all
- • Age between 35 and 45 years
- • Able to understand the written or spoken Dutch language
- • Gives consent for participating in surveys
- Exclusion Criteria:
- • Postmenopausal status at enrolment
- • Under the age of 35 or above 45
- • Previous salpingectomy of oophorectomy
- • Previous hysterectomy
- • Women with abnormal karyotype (such as Turner Syndrome and Fragile X syndrome)
- • Underwent chemotherapy or radiation
- • Unable to understand the written or spoken Dutch language
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Eindhoven, , Netherlands
Patients applied
Trial Officials
Jurgen MJ Piek, MD, PhD
Principal Investigator
Catharina Ziekenhuis
Joanne A de Hullu, MD, PhD
Principal Investigator
University Medical Center Nijmegen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials